{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:22Z","timestamp":1791438082334,"version":"4.3.3"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Avelumab, a programmed cell death ligand 1 blocking antibody, was approved for its first indication in Japan in September 2017 to treat unresectable Merkel cell carcinoma (MCC). Given that the pivotal JAVELIN Merkel 200 study only included a few Japanese patients, this post\u2010marketing surveillance (PMS) evaluated the safety and effectiveness outcomes of patients with MCC who received avelumab in general clinical practice in Japan. This prospective, non\u2010comparative, multicenter PMS included data from all patients with unresectable MCC who received avelumab between November 22, 2017 (avelumab launch date) and October 31, 2019. The primary objective was to evaluate avelumab safety (i.e., adverse events [AEs], adverse drug reactions [ADRs], and ADRs of safety specifications). The secondary objective was to evaluate avelumab effectiveness (i.e., objective response rate and overall survival [OS] rate). Seventy\u2010five evaluable patients were included, of whom 81.3% experienced AEs of any grade (57.3% experienced AEs of grade\u2009\u2265\u20093; 41.3% experienced AEs of grade 5) and 61.3% experienced ADRs (14.7% experienced ADRs of grade\u2009\u2265\u20093; no grade 5 ADRs were observed). The most common ADRs were pyrexia (18.7%), infusion related reaction (10.7%), and chills (6.7%). The most common ADRs of safety specifications were infusion reactions (any grade: <jats:italic>n<\/jats:italic>\u2009=\u200921 [28.0%]; grade 3 or 4: <jats:italic>n<\/jats:italic>\u2009=\u20093 [4.0%]), thyroid dysfunction (<jats:italic>n<\/jats:italic>\u2009=\u20097 [9.3%]), and hepatic function disorders (<jats:italic>n<\/jats:italic>\u2009=\u20094 [5.3%]). The median observation period was 51\u2009weeks. An objective response was achieved by 34\/75 patients (45.3%; complete response, 24.0%; partial response, 21.3%) and 6\u2010 and 12\u2010month OS rates were 77.7% and 59.6%, respectively. This PMS confirmed the clinical tolerability and effectiveness of avelumab in patients with MCC, with no new safety concerns. The risk\u2013benefit profile of avelumab was comparable with that observed in clinical trials and remains favorable for use in general clinical practice in Japan.<\/jats:p>","DOI":"10.1111\/1346-8138.17096","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T05:28:18Z","timestamp":1709530098000},"page":"475-483","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post\u2010marketing surveillance"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-3397","authenticated-orcid":false,"given":"Hisashi","family":"Uhara","sequence":"first","affiliation":[{"name":"Sapporo Medical University School of Medicine  Sapporo Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center Hospital and Research Institute  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Isei","sequence":"additional","affiliation":[{"name":"Osaka International Cancer Institution  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nagase","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saga\u2010Ken Medical Centre Koseikan  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzu","family":"Kambe","sequence":"additional","affiliation":[{"name":"Merck Biopharma Co., Ltd.  Tokyo Japan, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Merck Biopharma Co., Ltd.  Tokyo Japan, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Merck Biopharma Co., Ltd.  Tokyo Japan, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15875"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00048"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031328"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02756-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.739006"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.028"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.10.022"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001076"},{"key":"e_1_2_10_10_1","unstructured":"US Food and Drug Administration.BAVENCIO\u00ae (avelumab) injection for intravenous use: highlights of prescribing information [Internet].2017[cited 2022 Sep 13]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761078s000lbl.pdf"},{"key":"e_1_2_10_11_1","unstructured":"Merck.Bavencio (avelumab) approved for Merkel cell carcinoma in Japan [Internet].2017[cited 2022 Sep 13]. Available from:https:\/\/www.merckgroup.com\/en\/news\/bavencio\u2010japan\u2010approval\u20102017\u201009\u201027.html"},{"key":"e_1_2_10_12_1","unstructured":"US Food and Drug Administration.Supplement approval of avelumab for Merkel cell carcinoma [Internet].2023[cited 2023 Sept 25]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/761049Orig1s015ltr.pdf"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002646"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13845"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1250"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004904"},{"key":"e_1_2_10_19_1","unstructured":"Ministry of Health Labor and Welfare.Ministerial ordinance on standards for implementation of post\u2010marketing surveillance and studies [Internet].2022[cited 2023 Mar 07]. Available from:https:\/\/elaws.e\u2010gov.go.jp\/document?lawid=416M60000100171_20220520_504M60000100084"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_21_1","unstructured":"Merck.Bavencio\u00ae prescribing information [Internet].2023[cited 2023 Jul 10]. Available from:https:\/\/www.bavencio.jp\/product\/package_insert.pdf"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.07.002"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"e_1_2_10_24_1","first-page":"673","article-title":"Merkel cell carcinoma: a review of clinical management with focus on Asian patients","volume":"53","author":"Nakano E","year":"2023","journal-title":"JJCO"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19218"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0187"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:17:51Z","timestamp":1712074671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/1346-8138.17096"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17096","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}